These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16824756)

  • 41. Identification of a C-terminal regulatory motif in hepatitis C virus RNA-dependent RNA polymerase: structural and biochemical analysis.
    Lévêque VJ; Johnson RB; Parsons S; Ren J; Xie C; Zhang F; Wang QM
    J Virol; 2003 Aug; 77(16):9020-8. PubMed ID: 12885918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase.
    Nittoli T; Curran K; Insaf S; DiGrandi M; Orlowski M; Chopra R; Agarwal A; Howe AY; Prashad A; Floyd MB; Johnson B; Sutherland A; Wheless K; Feld B; O'Connell J; Mansour TS; Bloom J
    J Med Chem; 2007 May; 50(9):2108-16. PubMed ID: 17402724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis of new 4,5-dihydrofuranoindoles and their evaluation as HCV NS5B polymerase inhibitors.
    Velázquez F; Venkatraman S; Lesburg CA; Duca J; Rosenblum SB; Kozlowski JA; Njoroge FG
    Org Lett; 2012 Jan; 14(2):556-9. PubMed ID: 22220815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
    Alexandre FR; Badaroux E; Bilello JP; Bot S; Bouisset T; Brandt G; Cappelle S; Chapron C; Chaves D; Convard T; Counor C; Da Costa D; Dukhan D; Gay M; Gosselin G; Griffon JF; Gupta K; Hernandez-Santiago B; La Colla M; Lioure MP; Milhau J; Paparin JL; Peyronnet J; Parsy C; Pierra Rouvière C; Rahali H; Rahali R; Salanson A; Seifer M; Serra I; Standring D; Surleraux D; Dousson CB
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4323-4330. PubMed ID: 28835346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.
    Beaulieu PL; Bös M; Bousquet Y; Fazal G; Gauthier J; Gillard J; Goulet S; LaPlante S; Poupart MA; Lefebvre S; McKercher G; Pellerin C; Austel V; Kukolj G
    Bioorg Med Chem Lett; 2004 Jan; 14(1):119-24. PubMed ID: 14684311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current perspective of HCV NS5B inhibitors: a review.
    Patil VM; Gupta SP; Samanta S; Masand N
    Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis.
    Summa V; Petrocchi A; Matassa VG; Taliani M; Laufer R; De Francesco R; Altamura S; Pace P
    J Med Chem; 2004 Oct; 47(22):5336-9. PubMed ID: 15481971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Computational analysis of de novo evolution of hepatitis C virus NS5B polymerase inhibitors.
    Chen PY; Hsu WT; Jhuo MD; Ou CY; Cheng TH; Shih TC; Wu CH; Wu RS; Hsia TC; Chung JG
    In Vivo; 2011; 25(2):219-28. PubMed ID: 21471538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.
    Yi G; Deval J; Fan B; Cai H; Soulard C; Ranjith-Kumar CT; Smith DB; Blatt L; Beigelman L; Kao CC
    Antimicrob Agents Chemother; 2012 Feb; 56(2):830-7. PubMed ID: 22143520
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
    Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
    J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
    Cheng CC; Shipps GW; Yang Z; Kawahata N; Lesburg CA; Duca JS; Bandouveres J; Bracken JD; Jiang CK; Agrawal S; Ferrari E; Huang HC
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2119-24. PubMed ID: 20219368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.
    Beaulieu PL; Gillard J; Bykowski D; Brochu C; Dansereau N; Duceppe JS; Haché B; Jakalian A; Lagacé L; LaPlante S; McKercher G; Moreau E; Perreault S; Stammers T; Thauvette L; Warrington J; Kukolj G
    Bioorg Med Chem Lett; 2006 Oct; 16(19):4987-93. PubMed ID: 16908138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Schoenfeld RC; Bourdet DL; Brameld KA; Chin E; de Vicente J; Fung A; Harris SF; Lee EK; Le Pogam S; Leveque V; Li J; Lui AS; Najera I; Rajyaguru S; Sangi M; Steiner S; Talamas FX; Taygerly JP; Zhao J
    J Med Chem; 2013 Oct; 56(20):8163-82. PubMed ID: 24069953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of new quinizarin derivatives on both HCV NS5B RNA polymerase and HIV-1 reverse transcriptase associated ribonuclease H activities.
    Tramontano E; Kharlamova T; Zinzula L; Esposito F
    J Chemother; 2011 Oct; 23(5):273-6. PubMed ID: 22005058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.
    Harper S; Pacini B; Avolio S; Di Filippo M; Migliaccio G; Laufer R; De Francesco R; Rowley M; Narjes F
    J Med Chem; 2005 Mar; 48(5):1314-7. PubMed ID: 15743173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
    Brown JA; Thorpe IF
    Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.
    Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R
    J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.
    McKercher G; Beaulieu PL; Lamarre D; LaPlante S; Lefebvre S; Pellerin C; Thauvette L; Kukolj G
    Nucleic Acids Res; 2004; 32(2):422-31. PubMed ID: 14739234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases.
    Lee G; Piper DE; Wang Z; Anzola J; Powers J; Walker N; Li Y
    J Mol Biol; 2006 Apr; 357(4):1051-7. PubMed ID: 16476448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.